Achieving Acceleration to First-in-Human: MSD's Learnings on Platform Method Validation Strategy

Overview

Journal MAbs

Specialty Allergy & Immunology

Date 2025 Feb 18

PMID 39966106

Authors

Xiaoqing Hua

Jorge Quiroz

Joop Waterval

Brian Harrison

Maria DeBruin

Lynn Gennaro

Affiliations

Soon will be listed here.

Abstract

Over the past decades, the number of therapeutic protein pipelines in early-phase clinical studies has increased dramatically. The rapid growth in the pipeline underscores the need to accelerate early-stage development and enable fast first-in-human (FIH) trials to bring novel therapies to patients. Across the industry, various efforts have been developed to achieve this goal. In this communication, a platform analytical method validation approach developed and used by MSD for FIH programs is described. A case study from the release panel, a polysorbate 80 (PS-80) platform method is utilized to illustrate the workflow. In this approach, historical validation data within the same modality are summarized and supplemented with statistical analyses to justify a limited validation for future pipeline projects. The platform method validation strategy has reduced the overall validation timeline from up to 4 months to 1-2 months and has successfully been implemented in FIH filings. This communication provides insights to pharmaceutical companies interested in developing platform analytical method validation approaches for fast FIH studies.

References

Elzahhar P, Belal A, Elamrawy F, Helal N, Nounou M . Bioconjugation in Drug Delivery: Practical Perspectives and Future Perceptions. Methods Mol Biol. 2019; 2000:125-182. DOI: 10.1007/978-1-4939-9516-5_11. View

Fekete S, Guillarme D, Sandra P, Sandra K . Chromatographic, Electrophoretic, and Mass Spectrometric Methods for the Analytical Characterization of Protein Biopharmaceuticals. Anal Chem. 2015; 88(1):480-507. DOI: 10.1021/acs.analchem.5b04561. View

Hansel T, Kropshofer H, Singer T, Mitchell J, George A . The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov. 2010; 9(4):325-38. DOI: 10.1038/nrd3003. View

Crescioli S, Kaplon H, Chenoweth A, Wang L, Visweswaraiah J, Reichert J . Antibodies to watch in 2024. MAbs. 2024; 16(1):2297450. PMC: 10773713. DOI: 10.1080/19420862.2023.2297450. View

Puthenpurail A, Rathi H, Nauli S, Ally A . A BRIEF SYNOPSIS OF MONOCLONAL ANTIBODY FOR THE TREATMENT OF VARIOUS GROUPS OF DISEASES. World J Pharm Pharm Sci. 2022; 10(11):14-22. PMC: 8775886. View

Kochling J, Wu W, Hua Y, Guan Q, Castaneda-Merced J . A platform analytical quality by design (AQbD) approach for multiple UHPLC-UV and UHPLC-MS methods development for protein analysis. J Pharm Biomed Anal. 2016; 125:130-9. DOI: 10.1016/j.jpba.2016.03.031. View

Bolisetty P, Tremml G, Xu S, Khetan A . Enabling speed to clinic for monoclonal antibody programs using a pool of clones for IND-enabling toxicity studies. MAbs. 2020; 12(1):1763727. PMC: 7531531. DOI: 10.1080/19420862.2020.1763727. View

Schmieder V, Fieder J, Drerup R, Arango Gutierrez E, Guelch C, Stolzenberger J . Towards maximum acceleration of monoclonal antibody development: Leveraging transposase-mediated cell line generation to enable GMP manufacturing within 3 months using a stable pool. J Biotechnol. 2022; 349:53-64. DOI: 10.1016/j.jbiotec.2022.03.010. View

Smith M, Zhang S, Adams T, DiPaolo B, Dally J . Establishment and validation of a microfluidic capillary gel electrophoresis platform method for purity analysis of therapeutic monoclonal antibodies. Electrophoresis. 2017; 38(9-10):1353-1365. DOI: 10.1002/elps.201600519. View

10.

Wuchner K, Yi L, Chery C, Nikels F, Junge F, Crotts G . Industry Perspective on the use and Characterization of Polysorbates for Biopharmaceutical Products Part 1: Survey Report on Current State and Common Practices for Handling and Control of Polysorbates. J Pharm Sci. 2022; 111(5):1280-1291. DOI: 10.1016/j.xphs.2022.02.009. View

11.

Duivelshof B, Murisier A, Camperi J, Fekete S, Beck A, Guillarme D . Therapeutic Fc-fusion proteins: Current analytical strategies. J Sep Sci. 2020; 44(1):35-62. DOI: 10.1002/jssc.202000765. View

12.

Alhazmi H, Albratty M . Analytical Techniques for the Characterization and Quantification of Monoclonal Antibodies. Pharmaceuticals (Basel). 2023; 16(2). PMC: 9967501. DOI: 10.3390/ph16020291. View

13.

Cahuzac H, Devel L . Analytical Methods for the Detection and Quantification of ADCs in Biological Matrices. Pharmaceuticals (Basel). 2020; 13(12). PMC: 7765153. DOI: 10.3390/ph13120462. View

14.

Wuchner K, Yi L, Chery C, Nikels F, Junge F, Crotts G . Industry Perspective on the Use and Characterization of Polysorbates for Biopharmaceutical Products Part 2: Survey Report on Control Strategy Preparing for the Future. J Pharm Sci. 2022; 111(11):2955-2967. DOI: 10.1016/j.xphs.2022.08.021. View

15.

Pantaleo G, Correia B, Fenwick C, Joo V, Perez L . Antibodies to combat viral infections: development strategies and progress. Nat Rev Drug Discov. 2022; 21(9):676-696. PMC: 9207876. DOI: 10.1038/s41573-022-00495-3. View

16.

Khetan R, Curtis R, Deane C, Hadsund J, Kar U, Krawczyk K . Current advances in biopharmaceutical informatics: guidelines, impact and challenges in the computational developability assessment of antibody therapeutics. MAbs. 2022; 14(1):2020082. PMC: 8812776. DOI: 10.1080/19420862.2021.2020082. View

17.

Halim V, de Jonker M, Esteve C, Assenberg R, Balog C . Novel EDTA mediated ethanol protein precipitation method and the application for polysorbate quantification in high protein concentration biopharmaceuticals. J Pharm Biomed Anal. 2024; 245:116145. DOI: 10.1016/j.jpba.2024.116145. View

18.

Martos A, Berger M, Kranz W, Spanopoulou A, Menzen T, Friess W . Novel High-Throughput Assay for Polysorbate Quantification in Biopharmaceutical Products by Using the Fluorescent Dye DiI. J Pharm Sci. 2019; 109(1):646-655. DOI: 10.1016/j.xphs.2019.10.013. View

19.

Einsele H, Borghaei H, Orlowski R, Subklewe M, Roboz G, Zugmaier G . The BiTE (bispecific T-cell engager) platform: Development and future potential of a targeted immuno-oncology therapy across tumor types. Cancer. 2020; 126(14):3192-3201. DOI: 10.1002/cncr.32909. View

20.

Ji E, Lee S . Antibody-Based Therapeutics for Atherosclerosis and Cardiovascular Diseases. Int J Mol Sci. 2021; 22(11). PMC: 8199089. DOI: 10.3390/ijms22115770. View